A/Prof Maija Kohonen-Corish

A/Prof Maija Kohonen-Corish

Lab Head - Colon and Lung Cancer Research

Senior Research Fellow

Conjoint/Adjunct Role(s)

Conjoint Associate Professor, School of Medicine, University of Western Sydney
Conjoint Senior Lecturer, St Vincent's Clinical School, Faculty of Medicine, UNSW Australia

Associate Professor Kohonen-Corish has a 21-year track record of discovery in cancer research, including the genetic basis of colon cancer, translational research in colon and lung cancer and the development of mouse models of cancer. She completed her PhD in the Department of Human Genetics at The John Curtin School of Medical Research in 1988. She established a new cancer genetics laboratory (1991-2000) at The John Curtin School, which was one of the first in Australia to study the genetic basis of Lynch Syndrome. She has been at the Garvan Institute since 2002.

Research Interests

Colon cancer genetics and biology
Mouse models of colon cancer
Translational Colon and Lung Cancer

Awards and Honours

Cancer Institute NSW Career Development Fellowship 2005, 2008, 2011
MHGSA Specialist Accreditation in Molecular Genetics, Human Genetics Society of Australasia, 2005

Education

1988 - PhD, Human Genetics, Australian National University, Canberra - Australia
1983 - MSc, Genetics, University of Helsinki - Finland
1982 - BSc, University of Helsinki - Finland

Selected Publications

Mladenova D, Pangon L, Currey N, Irvin Ng, Musgrove EA, Grey ST, Kohonen-Corish MRJ. Sulindac sulfide activates NF-kB signalling in colorectal cancer cells. Cell Communication and Signaling (in press)

Pangon L, Van Kralingen C, Abas M, Daly RJ, Musgrove EA, Kohonen-Corish MR. The PDZ-binding motif of MCC is phosphorylated at position -1 and controls lamellipodia formation in colon epithelial cells. Biochim Biophys Acta 2012;1823:1058-67.

Mladenova D, Daniel JJ, Dahlstrom JE, Bean E, Gupta R, Pickford R, Currey N, Musgrove EA, Kohonen-Corish MRJ. The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 2011; 60: 350-360.

Kohonen-Corish MR, Al-Aama JY, Auerbach AD, Axton M, Barash CI, Bernstein I, Beroud C, Burn J, Cunningham F, Cutting GR, den Dunnen JT, Greenblatt MS, Kaput J, Katz M, Lindblom A, Macrae F, Maglott D, Moslein G, Povey S, Ramesar R, Richards S, Seminara D, Sobrido MJ, Tavtigian S, Taylor G, Vihinen M, Winship I, Cotton RG. How to catch all those mutations--the report of the third Human Variome Project Meeting, UNESCO Paris, May 2010. Hum Mutat 2010; 31: 1374-1381.

Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, Sutherland RL, Kennedy C, McCaughan B, Kohonen-Corish MR. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008;99:375-82.

Kohonen-Corish MR, Sigglekow ND, Susanto J, Chapuis PH, Bokey EL, Dent OF, Chan C, Lin BP, Seng TJ, Laird PW, Young J, Leggett BA, Jass JR, Sutherland RL. Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene 2007;26:4435-41.

Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005;23:2318-24.

Kohonen-Corish MR, Daniel JJ, te Riele H, Buffinton GD, Dahlstrom JE. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. Cancer Res 2002;62:2092-7.

Kohonen-Corish M, Ross VL, Doe WF, Kool DA, Edkins E, Faragher I, Wijnen J, Khan PM, Macrae F, St John DJ. RNA-based mutation screening in hereditary nonpolyposis colorectal cancer. Am J Hum Genet 1996;59:818-24.

Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol 1990;20:157-61.

Kohonen-Corish MR, Serjeantson SW. HLA-DR beta gene DNA polymorphisms revealed by Taq I correlate with HLA-DR specificities. Hum Immunol 1986;15:263-71.

A/Prof Maija Kohonen-Corish